214 related articles for article (PubMed ID: 33631102)
1. The effect of a microbial ecosystem therapeutic (MET-2) on recurrent Clostridioides difficile infection: a phase 1, open-label, single-group trial.
Kao D; Wong K; Franz R; Cochrane K; Sherriff K; Chui L; Lloyd C; Roach B; Bai AD; Petrof EO; Allen-Vercoe E
Lancet Gastroenterol Hepatol; 2021 Apr; 6(4):282-291. PubMed ID: 33631102
[TBL] [Abstract][Full Text] [Related]
2. Faecal microbiota transplantation for
Terveer EM; Vendrik KE; Ooijevaar RE; Lingen EV; Boeije-Koppenol E; Nood EV; Goorhuis A; Bauer MP; van Beurden YH; Dijkgraaf MG; Mulder CJ; Vandenbroucke-Grauls CM; Seegers JF; van Prehn J; Verspaget HW; Kuijper EJ; Keller JJ
United European Gastroenterol J; 2020 Dec; 8(10):1236-1247. PubMed ID: 32990503
[TBL] [Abstract][Full Text] [Related]
3. Oral, capsulized, frozen fecal microbiota transplantation for relapsing Clostridium difficile infection.
Youngster I; Russell GH; Pindar C; Ziv-Baran T; Sauk J; Hohmann EL
JAMA; 2014 Nov; 312(17):1772-8. PubMed ID: 25322359
[TBL] [Abstract][Full Text] [Related]
4. Effect of Fecal Microbiota Transplantation on Recurrence in Multiply Recurrent Clostridium difficile Infection: A Randomized Trial.
Kelly CR; Khoruts A; Staley C; Sadowsky MJ; Abd M; Alani M; Bakow B; Curran P; McKenney J; Tisch A; Reinert SE; Machan JT; Brandt LJ
Ann Intern Med; 2016 Nov; 165(9):609-616. PubMed ID: 27547925
[TBL] [Abstract][Full Text] [Related]
5. Faecal microbiota transplantation for first or second Clostridioides difficile infection (EarlyFMT): a randomised, double-blind, placebo-controlled trial.
Baunwall SMD; Andreasen SE; Hansen MM; Kelsen J; Høyer KL; Rågård N; Eriksen LL; Støy S; Rubak T; Damsgaard EMS; Mikkelsen S; Erikstrup C; Dahlerup JF; Hvas CL
Lancet Gastroenterol Hepatol; 2022 Dec; 7(12):1083-1091. PubMed ID: 36152636
[TBL] [Abstract][Full Text] [Related]
6. Faecal microbiota transplantation for recurrent Clostridioides difficile infection: experience with lyophilized oral capsules.
Reigadas E; Bouza E; Olmedo M; Vázquez-Cuesta S; Villar-Gómara L; Alcalá L; Marín M; Rodríguez-Fernández S; Valerio M; Muñoz P
J Hosp Infect; 2020 Jun; 105(2):319-324. PubMed ID: 31883938
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of lyophilised bacteria-rich faecal sediment and supernatant with reduced bacterial count for treating patients with
Varga A; Makszin L; Bufa A; Sipos D; Kása P; Pál S; Rosenstiel P; Sommer F; Kocsis B; Péterfi Z
Front Cell Infect Microbiol; 2023; 13():1041384. PubMed ID: 36756616
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of RBX2660 in PUNCH CD3, a Phase III, Randomized, Double-Blind, Placebo-Controlled Trial with a Bayesian Primary Analysis for the Prevention of Recurrent Clostridioides difficile Infection.
Khanna S; Assi M; Lee C; Yoho D; Louie T; Knapple W; Aguilar H; Garcia-Diaz J; Wang GP; Berry SM; Marion J; Su X; Braun T; Bancke L; Feuerstadt P
Drugs; 2022 Oct; 82(15):1527-1538. PubMed ID: 36287379
[TBL] [Abstract][Full Text] [Related]
9. Durable reduction of Clostridioides difficile infection recurrence and microbiome restoration after treatment with RBX2660: results from an open-label phase 2 clinical trial.
Orenstein R; Dubberke ER; Khanna S; Lee CH; Yoho D; Johnson S; Hecht G; DuPont HL; Gerding DN; Blount KF; Mische S; Harvey A
BMC Infect Dis; 2022 Mar; 22(1):245. PubMed ID: 35279084
[TBL] [Abstract][Full Text] [Related]
10. Longitudinal microbiome analysis of single donor fecal microbiota transplantation in patients with recurrent Clostridium difficile infection and/or ulcerative colitis.
Mintz M; Khair S; Grewal S; LaComb JF; Park J; Channer B; Rajapakse R; Bucobo JC; Buscaglia JM; Monzur F; Chawla A; Yang J; Robertson CE; Frank DN; Li E
PLoS One; 2018; 13(1):e0190997. PubMed ID: 29385143
[TBL] [Abstract][Full Text] [Related]
11. Changes in microbiota composition, bile and fatty acid metabolism, in successful faecal microbiota transplantation for Clostridioides difficile infection.
Brown JR; Flemer B; Joyce SA; Zulquernain A; Sheehan D; Shanahan F; O'Toole PW
BMC Gastroenterol; 2018 Aug; 18(1):131. PubMed ID: 30153805
[TBL] [Abstract][Full Text] [Related]
12. Randomised clinical trial: faecal microbiota transplantation for recurrent Clostridum difficile infection - fresh, or frozen, or lyophilised microbiota from a small pool of healthy donors delivered by colonoscopy.
Jiang ZD; Ajami NJ; Petrosino JF; Jun G; Hanis CL; Shah M; Hochman L; Ankoma-Sey V; DuPont AW; Wong MC; Alexander A; Ke S; DuPont HL
Aliment Pharmacol Ther; 2017 Apr; 45(7):899-908. PubMed ID: 28220514
[TBL] [Abstract][Full Text] [Related]
13. Successful treatment of Clostridioidesdifficile infection with single-donorfaecal microbiota transplantation capsules.
Cold F; Svensson CK; Christensen AH; Günther S; Petersen AM; Hansen LH; Helms M
Dan Med J; 2022 Jan; 69(2):. PubMed ID: 35088703
[TBL] [Abstract][Full Text] [Related]
14. Fecal microbiota transplantation for recurrent Clostridium difficile infection in hematopoietic stem cell transplant recipients.
Webb BJ; Brunner A; Ford CD; Gazdik MA; Petersen FB; Hoda D
Transpl Infect Dis; 2016 Aug; 18(4):628-33. PubMed ID: 27214585
[TBL] [Abstract][Full Text] [Related]
15. SER-109 (VOWST
Blair HA
Drugs; 2024 Mar; 84(3):329-336. PubMed ID: 38441806
[TBL] [Abstract][Full Text] [Related]
16. Safety and Tolerability of SER-109 as an Investigational Microbiome Therapeutic in Adults With Recurrent Clostridioides difficile Infection: A Phase 3, Open-Label, Single-Arm Trial.
Sims MD; Khanna S; Feuerstadt P; Louie TJ; Kelly CR; Huang ES; Hohmann EL; Wang EEL; Oneto C; Cohen SH; Berenson CS; Korman L; Lee C; Lashner B; Kraft CS; Ramesh M; Silverman M; Pardi DS; De A; Memisoglu A; Lombardi DA; Hasson BR; McGovern BH; von Moltke L;
JAMA Netw Open; 2023 Feb; 6(2):e2255758. PubMed ID: 36780159
[TBL] [Abstract][Full Text] [Related]
17. Oral, frozen fecal microbiota transplant (FMT) capsules for recurrent Clostridium difficile infection.
Youngster I; Mahabamunuge J; Systrom HK; Sauk J; Khalili H; Levin J; Kaplan JL; Hohmann EL
BMC Med; 2016 Sep; 14(1):134. PubMed ID: 27609178
[TBL] [Abstract][Full Text] [Related]
18. Faecal microbiota transplantation for treatment of recurrent or refractory
Lui RN; Wong SH; Lau LHS; Chan TT; Cheung KCY; Li A; Chin ML; Tang W; Ching JYL; Lam KLY; Chan PKS; Wu JCY; Sung JJY; Chan FKL; Ng SC
Hong Kong Med J; 2019 Jun; 25(3):178-182. PubMed ID: 31178437
[TBL] [Abstract][Full Text] [Related]
19. Complete Microbiota Engraftment Is Not Essential for Recovery from Recurrent Clostridium difficile Infection following Fecal Microbiota Transplantation.
Staley C; Kelly CR; Brandt LJ; Khoruts A; Sadowsky MJ
mBio; 2016 Dec; 7(6):. PubMed ID: 27999162
[TBL] [Abstract][Full Text] [Related]
20. SER-109, an Oral Microbiome Therapy for Recurrent
Feuerstadt P; Louie TJ; Lashner B; Wang EEL; Diao L; Bryant JA; Sims M; Kraft CS; Cohen SH; Berenson CS; Korman LY; Ford CB; Litcofsky KD; Lombardo MJ; Wortman JR; Wu H; Auniņš JG; McChalicher CWJ; Winkler JA; McGovern BH; Trucksis M; Henn MR; von Moltke L
N Engl J Med; 2022 Jan; 386(3):220-229. PubMed ID: 35045228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
